01—Abstract
Summary
Summary of the 10-K filed February 24, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s 2022 Form 10-K highlights a pivotal year for the company, marked by significant revenue growth primarily driven by its COVID-19 vaccine, Spikevax.
Despite generating over $18.4 billiona in product sales from Spikevax and its Omicron-targeting boosters, the company anticipates a decline in COVID-19 vaccine sales in 2023 as the market transitions towards an endemic phase. This shift presents challenges related to market fragmentation, seasonality, and increased distribution costs. Moderna continues to aggressively invest in its diverse mRNA pipeline, with 48 development programs across various modalities, including infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions.
Key advancements include positive Phase 3 data for its RSV vaccine candidate, mRNA-1345, and promising Phase 2 results for its personalized cancer vaccine (PCV), mRNA-4157, in combination with Merck's Keytruda. The company is also expanding its manufacturing capabilities globally through strategic partnerships and government agreements.
However, Moderna faces substantial risks, including the evolving COVID-19 vaccine market dynamics, intense competition, potential manufacturing and supply chain disruptions, and the inherent uncertainties in drug development and regulatory approvals. The company's financial performance remains heavily reliant on its COVID-19 vaccine, and achieving long-term sustainable profitability will depend on the successful commercialization of its broader pipeline.
02—Key points
Key Highlights
- Moderna generated $18.4 billion in product sales from its COVID-19 vaccines in 2022, with an additional $440 million from collaboration revenue and $388 million from grant revenue, totaling $19.26 billion in total revenue.
- The company anticipates a decline in COVID-19 vaccine sales in 2023 due to the market transition to an endemic phase, facing challenges from a fragmented customer base, seasonality, and increased costs.
- Moderna maintains a robust pipeline with 48 development programs across seven modalities, including significant progress in respiratory vaccines (RSV, Flu), personalized cancer vaccines (PCV), and latent virus vaccines (CMV).
- Positive Phase 3 topline data for the RSV vaccine candidate (mRNA-1345) and promising Phase 2 results for the personalized cancer vaccine (mRNA-4157) in combination with Keytruda were announced.
- The company is expanding its global manufacturing footprint through strategic agreements with governments in Australia, Canada, and the UK, and investing in a new Moderna Science Center.
- Moderna faces significant risks including intense competition, manufacturing and supply chain complexities, evolving regulatory landscapes for COVID-19 vaccines, and the inherent uncertainties of drug development.
- The company's financial future relies heavily on the successful development and commercialization of its broader pipeline beyond COVID-19 vaccines to achieve long-term sustainable profitability.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2022, Moderna, Inc. kept $0.43.
- Revenue$19.26B100.0%
- Cost of revenue−$5.42B28.1%
- Gross profit$13.85B71.9%
- Operating costs−$4.43B23.0%
- Operating income$9.42B48.9%
- Interest, other & tax−$1.06B5.5%
- Net income$8.36B43.4%
Where FY2022 revenue went
$19.26B- Net income: $8.36B, 43% of revenue
- Cost of revenue: $5.42B, 28% of revenue
- R&D: $3.29B, 17% of revenue
- Other operating costs: $1.13B, 5.9% of revenue
- Interest, other & tax: $1.06B, 5.5% of revenue
Kept 43% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 24, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $19.26B$18.47B | +4.3% |
| Cost of Revenue | $5.42B$2.62B | +107.0% |
| Gross Profit | $13.85B$15.85B | −12.7% |
| R&D Expenses | $3.29B$1.99B | +65.5% |
| Operating Expenses | $9.84B$5.17B | +90.2% |
| Operating Income | $9.42B$13.30B | −29.2% |
| Net Income | $8.36B$12.20B | −31.5% |
| EPS (Basic) | $21.26$30.31 | −29.9% |
| EPS (Diluted) | $20.12$28.29 | −28.9% |
| Shares Outstanding (Basic) | 394.00M403.00M | −2.2% |
| Shares Outstanding (Diluted) | 416.00M431.00M | −3.5% |
05—Questions
Frequently Asked Questions
What is Moderna's primary source of revenue, and what are the expectations for this revenue stream in the near future?
Moderna's primary source of revenue is product sales from its COVID-19 vaccine, Spikevax, and its Omicron-targeting boosters, which generated $18.4 billion in 2022. However, the company anticipates a decline in COVID-19 vaccine sales in 2023 as the market shifts towards an endemic phase, facing challenges such as market fragmentation, seasonality, and increased distribution costs.
What are Moderna's key development programs and pipeline advancements mentioned in the 10-K filing?
Moderna has a diverse pipeline of 48 development programs across seven modalities. Key advancements include positive Phase 3 topline efficacy results for its RSV vaccine candidate (mRNA-1345), promising Phase 2 results for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda, and ongoing Phase 3 studies for its CMV and seasonal flu vaccine candidates. The company is also advancing combination respiratory vaccines and exploring treatments for rare diseases and cardiovascular conditions.
What are the major risks and challenges Moderna faces according to the 10-K filing?
Moderna faces several significant risks, including the evolving market dynamics for COVID-19 vaccines, intense competition from established pharmaceutical companies, potential manufacturing and supply chain disruptions, regulatory uncertainties related to vaccine updates for variants, and the inherent lengthy and uncertain nature of clinical development and regulatory approval processes for its broader pipeline.
How is Moderna expanding its manufacturing capabilities and global presence?
Moderna is expanding its manufacturing capabilities through internal investments and strategic partnerships. This includes building state-of-the-art mRNA manufacturing facilities in Australia, Canada, and the UK through agreements with their respective governments. The company is also investing in a new, larger Moderna Science Center in Cambridge, Massachusetts.
06—Continue